Comparison of tacrolimus and cyclosporine for immunosuppression after renal transplantation : an updated systematic review and meta-analysis
المؤلفون المشاركون
Azarfar, Anoush
Mahrad Majd, Hasan
Imad Zadah, Maryam
Muradi, Ali
Golsorkhi, Mohadese
Khuzai, Mahmud Rida
Ismaili, Muhammad
Aval, Shapour Badi
Salihi, Maryam
Ravanshad, Yalda
المصدر
Saudi Journal of Kidney Diseases and Transplantation
العدد
المجلد 29، العدد 6 (31 ديسمبر/كانون الأول 2018)، ص ص. 1376-1385، 10ص.
الناشر
تاريخ النشر
2018-12-31
دولة النشر
السعودية
عدد الصفحات
10
الملخص EN
Kidney transplantation is usually followed by immunosuppressive therapy to prevent early rejection and prolong graft survival.
The calcineurin inhibitors (CNIs) represent the most commonly used agents.
However, available evidence suggests the poor outcome over the long term, maybe be due to the potential nephrotoxicity associated with CNIs.
Several randomized trials have compared tacrolimus (TAC) with cyclosporine, to find the optimal agent for renal transplantation; however, studies have shown conflicting results.
The aim of this study was to systematically review and update the evidence for the benefits and harm of TAC versus cyclosporine as the primary immunosuppression after renal transplantation.
The study was a systematic review and meta-analysis.
An electronic literature search was conducted to identify appropriated trial studies.
The outcomes were presented as relative risk (RR), with 95% confidence intervals (CI).
Statistical analysis used was meta-analysis.
Twenty-one eligible randomized controlled trials were included in this systematic review.
TAC was significantly superior to cyclosporine considering the total effect size of graft loss (RR 0.089; 95% CI0.057-0.122, P <0.001), acute rejection (RR 0.638; 95% CI 0.571-0.713, P <0.001) and hypercholeste-rolemia (RR 0.634; 95% CI, 0.539-0.746, P <0.001).
On the contrary, cyclosporine seemed to be significantly superior to TAC with regard to diabetes (RR 1.891; 95% CI 1.522-2.350, P <0.001).
However, no significant differences between the two CNIs were found with regard to mortality, infection, and hypertension.
The review indicates that TAC is significantly superior to cyclosporine regarding graft loss, acute rejection, and hypercholesterolemia, but cyclosporine seems to be significantly superior to TAC regarding diabetes.
However, further large randomized trials are suggested.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Azarfar, Anoush& Ravanshad, Yalda& Mahrad Majd, Hasan& Ismaili, Muhammad& Aval, Shapour Badi& Imad Zadah, Maryam…[et al.]. 2018. Comparison of tacrolimus and cyclosporine for immunosuppression after renal transplantation : an updated systematic review and meta-analysis. Saudi Journal of Kidney Diseases and Transplantation،Vol. 29, no. 6, pp.1376-1385.
https://search.emarefa.net/detail/BIM-896417
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Azarfar, Anoush…[et al.]. Comparison of tacrolimus and cyclosporine for immunosuppression after renal transplantation : an updated systematic review and meta-analysis. Saudi Journal of Kidney Diseases and Transplantation Vol. 29, no. 6 (Nov. / Dec. 2018), pp.1376-1385.
https://search.emarefa.net/detail/BIM-896417
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Azarfar, Anoush& Ravanshad, Yalda& Mahrad Majd, Hasan& Ismaili, Muhammad& Aval, Shapour Badi& Imad Zadah, Maryam…[et al.]. Comparison of tacrolimus and cyclosporine for immunosuppression after renal transplantation : an updated systematic review and meta-analysis. Saudi Journal of Kidney Diseases and Transplantation. 2018. Vol. 29, no. 6, pp.1376-1385.
https://search.emarefa.net/detail/BIM-896417
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references : p. 1384-1385
رقم السجل
BIM-896417
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر